Patents by Inventor Ralph R. Weichselbaum

Ralph R. Weichselbaum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180256678
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more inhibitors of the JAK/STAT pathway which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Patent number: 9790504
    Abstract: Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: October 17, 2017
    Assignee: The University of Chicago
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Publication number: 20170268001
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: March 15, 2017
    Publication date: September 21, 2017
    Inventors: Nikolai N. Khodarev, Diana Rose E. Ranoa, Sean P. Pitroda, Ralph R. Weichselbaum
  • Publication number: 20160369353
    Abstract: Methods and compositions are provided for predicting efficacy of a DNA damaging agent in a cancer patient or treating a cancer patient with a DNA damaging agent after evaluating efficacy. In some embodiments, an algorithm is used to evaluate efficacy and treatment.
    Type: Application
    Filed: March 23, 2016
    Publication date: December 22, 2016
    Inventors: Sean P. Pitroda, Ralph R. Weichselbaum, Philip P. Connell
  • Publication number: 20160367627
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more inhibitors of the JAK/STAT pathway which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: June 24, 2014
    Publication date: December 22, 2016
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Publication number: 20160222387
    Abstract: Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: May 21, 2014
    Publication date: August 4, 2016
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Patent number: 9198914
    Abstract: The present invention concerns methods and compositions involving inhibitors and enhancers of RAD51, a protein involved in homologous recombination. In some embodiments, the present invention concerns methods for stimulating homologous recombination, which has a number of significant research and clinical applications. In certain other embodiments, there are methods for protecting cells using a compound that enhances RAD51 activity. Such enhancers may also be employed to prevent or reduce damage to cells that may be caused by DNA damaging agents. In other embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 enhancer or inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: December 1, 2015
    Assignee: The University of Chicago
    Inventors: Philip P. Connell, Douglas K. Bishop, Ralph R. Weichselbaum
  • Publication number: 20150024008
    Abstract: Disclosed are cancer vaccines comprising senescent cells and methods of using and preparing the vaccines.
    Type: Application
    Filed: November 21, 2012
    Publication date: January 22, 2015
    Inventors: Stephen Kron, Ralph R. Weichselbaum, Elena Efimova, Yuru Meng, Amy Flor
  • Patent number: 8772261
    Abstract: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: July 8, 2014
    Assignee: Arch Development Corporation
    Inventors: Ralph R. Weichselbaum, Bernard Roizman, Richard J. Whitley
  • Publication number: 20140142103
    Abstract: The present invention concerns methods and compositions involving inhibitors and enhancers of RAD51, a protein involved in homologous recombination. In some embodiments, the present invention concerns methods for stimulating homologous recombination, which has a number of significant research and clinical applications. In certain other embodiments, there are methods for protecting cells using a compound that enhances RAD51 activity. Such enhancers may also be employed to prevent or reduce damage to cells that may be caused by DNA damaging agents. In other embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 enhancer or inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.
    Type: Application
    Filed: November 7, 2013
    Publication date: May 22, 2014
    Applicant: The University of Chicago
    Inventors: Philip P. Connell, Douglas K. Bishop, Ralph R. Weichselbaum
  • Patent number: 8597949
    Abstract: The present invention concerns methods and compositions involving inhibitors and enhancers of RAD51, a protein involved in homologous recombination. In some embodiments, the present invention concerns methods for stimulating homologous recombination, which has a number of significant research and clinical applications. In certain other embodiments, there are methods for protecting cells using a compound that enhances RAD51 activity. Such enhancers may also be employed to prevent or reduce damage to cells that may be caused by DNA damaging agents. In other embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 enhancer or inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: December 3, 2013
    Assignee: The University of Chicago
    Inventors: Philip P. Connell, Douglas K. Bishop, Ralph R. Weichselbaum
  • Publication number: 20130164811
    Abstract: The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.
    Type: Application
    Filed: June 26, 2012
    Publication date: June 27, 2013
    Applicants: DANA-FARBER CANCER INSTITUTE, ARCH DEVELOPMENT CORPORATION
    Inventors: Donald KUFE, Ralph R. WEICHSELBAUM
  • Patent number: 8318691
    Abstract: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: November 27, 2012
    Assignees: Arch Development Corporation, UAB Research Foundation
    Inventors: Ralph R. Weichselbaum, Bernard Roizman, Richard J. Whitley
  • Publication number: 20110274661
    Abstract: The disclosure provides materials and methods for the treatment of cells exhibiting a cell proliferative disorder with a herpes simplex virus having a deficiency in the expression of active ICP34.5 and comprising an expression control element effective in modulating at least one component of the MEK pathway to ensure that infected cells are MEK+. Cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, are amenable to treatment using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.
    Type: Application
    Filed: August 7, 2009
    Publication date: November 10, 2011
    Applicant: The University of Chicago
    Inventors: Alice P. Poon, Ralph R. Weichselbaum, Bernard Roizman
  • Patent number: 8034791
    Abstract: The present invention relates to methods of inducing expression of a polynucleotide encoding a therapeutic polypeptide, e.g., TNF-?, in a cell comprising contacting the cell with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding the polypeptide, and at least one chemotherapeutic agent, wherein the chemotherapeutic agent induces expression of the polypeptide. The invention also relates to methods of inhibiting a neoplastic cell, comprising contacting the cell with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding TNF-? and a chemotherapeutic agent. The present invention further relates to methods of inhibiting or reducing the growth of a tumor in a subject, comprising co-administering to the subject a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding TNF-? and a chemotherapeutic agent, wherein the co-administration inhibits or reduces the ability of the tumor to grow.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: October 11, 2011
    Assignees: The University of Chicago, Dana-Farber Cancer Institute
    Inventors: Ralph R. Weichselbaum, Donald W. Kufe, Mitchell Posner, Helena Mauceri, James O. Park
  • Publication number: 20110091375
    Abstract: Disclosed are methods of synergistically inhibiting growth of a glioma cell comprising contacting the cell with temozolomide and TNF?, or with temozolomide, TNF?, and radiation. Also disclosed are methods of synergistically inhibiting growth of a glioma in a human cancer patient comprising administering temozolomide and TNF?, or with temozolomide, TNF?, and radiation. Pharmaceutical combinations and therapeutic combinations suitable for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: December 17, 2010
    Publication date: April 21, 2011
    Applicants: THE UNIVERSITY OF CHICAGO, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Ralph R. Weichselbaum, Donald W. Kufe, Bakhtiar Yamini
  • Patent number: 7919310
    Abstract: The present disclosure demonstrates the successful use of constitutive promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or patients in conjunction with radiation exposure. Also disclosed are pharmacological preparations to be used to increase the levels of radiosensitizing compounds such as TNF-?, or radioprotective compounds such as MnSOD, in specified tissues or tumors of a subject.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: April 5, 2011
    Assignees: The University of Chicago, Dana-Farber Cancer Institute
    Inventors: Ralph R. Weichselbaum, Dennis E. Hallahan, Donald W. Kufe, Vikas P. Sukhatme
  • Publication number: 20110053240
    Abstract: The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.
    Type: Application
    Filed: October 13, 2010
    Publication date: March 3, 2011
    Applicants: ARCH DEVELOPMENT CORPORATION, DANA-FARBER CANCER INSTITUTE
    Inventors: Donald KUFE, Ralph R. WEICHSELBAUM
  • Publication number: 20110046211
    Abstract: The present invention relates to therapeutic combinations and methods of inhibiting the proliferation of cancerous cells, the abnormal growth of cells, and tumor cell growth using the combination of a hedgehog inhibitor with chemotherapy and/or radiation therapy. The present invention also relates to methods of enhancing the antiproliferative effect of chemotherapy and/or radiation therapy in a mammalian cancer patient undergoing either chemotherapy or radiation or a combination of radiation and chemotherapy by co-administering a therapeutically amount of a hedgehog inhibitor, concurrently or sequentially, with the chemotherapy and/or radiation therapy.
    Type: Application
    Filed: October 27, 2010
    Publication date: February 24, 2011
    Applicant: The University of Chicago
    Inventors: Ralph R. Weichselbaum, Zahra Shafaee, Wei Du
  • Publication number: 20110002890
    Abstract: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.
    Type: Application
    Filed: June 7, 2010
    Publication date: January 6, 2011
    Applicants: UAB RESEARCH FOUNDATION
    Inventors: Ralph R. Weichselbaum, Bernard Roizman, Richard J. Whitley